{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IR",
    "query": {
      "intervention": "Placebo IR"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 135,
    "total_pages": 14,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+IR&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-05T03:39:53.020Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01010750",
      "title": "Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Attention-Deficit Hyperactivity Disorder"
      ],
      "interventions": [
        {
          "name": "Lisdexamfetamine Dimesylate (LDX)",
          "type": "DRUG"
        },
        {
          "name": "Immediate Release Mixed Amphetamine Salts (MAS-IR)",
          "type": "DRUG"
        },
        {
          "name": "LDX Placebo + MAS-IR Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 18,
      "start_date": "2010-01-05",
      "completion_date": "2010-03-28",
      "has_results": true,
      "last_update_posted_date": "2021-06-14",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01010750"
    },
    {
      "nct_id": "NCT00357994",
      "title": "Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Advanced Parkinson's Disease"
      ],
      "interventions": [
        {
          "name": "Levodopa carbidopa intestinal gel (LCIG)",
          "type": "DRUG"
        },
        {
          "name": "Placebo gel",
          "type": "DRUG"
        },
        {
          "name": "Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo (PBO) oral capsules",
          "type": "DRUG"
        },
        {
          "name": "CADD-Legacy® 1400 ambulatory infusion pump",
          "type": "DEVICE"
        },
        {
          "name": "PEG tube",
          "type": "DEVICE"
        },
        {
          "name": "J-tube",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DEVICE"
      ],
      "sponsor": "AbbVie (prior sponsor, Abbott)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2009-01",
      "completion_date": "2011-10",
      "has_results": true,
      "last_update_posted_date": "2015-01-16",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Englewood, Colorado • Washington D.C., District of Columbia + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Bradenton",
          "state": "Florida"
        },
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00357994"
    },
    {
      "nct_id": "NCT01904409",
      "title": "Dose-ranging Study of Rifaximin Soluble Solid Dispersion (SSD) Tablets for the Prevention of Complications of Early Decompensated Liver Cirrhosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 40 mg IR tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 80 mg IR tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 40 mg SER tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 80 mg SER tablet",
          "type": "DRUG"
        },
        {
          "name": "Rifaximin SSD 80mgIR/80mgSER tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 420,
      "start_date": "2013-06",
      "completion_date": "2015-07",
      "has_results": false,
      "last_update_posted_date": "2019-10-23",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 113,
      "location_summary": "Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 94 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Dothan",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Artesia",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01904409"
    },
    {
      "nct_id": "NCT01838681",
      "title": "Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Major Depressive Disorder"
      ],
      "interventions": [
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Brexpiprazole",
          "type": "DRUG"
        },
        {
          "name": "ADT",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 1986,
      "start_date": "2013-06",
      "completion_date": "2016-06",
      "has_results": true,
      "last_update_posted_date": "2017-08-09",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Cerritos, California • Temecula, California + 4 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Cerritos",
          "state": "California"
        },
        {
          "city": "Temecula",
          "state": "California"
        },
        {
          "city": "Flowood",
          "state": "Mississippi"
        },
        {
          "city": "Brooklyn",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01838681"
    },
    {
      "nct_id": "NCT01210560",
      "title": "Dose-finding Study of New Tolvaptan Formulation in Subjects With ADPKD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autosomal Dominant Polycystic Kidney Disease"
      ],
      "interventions": [
        {
          "name": "Tolvaptan MR",
          "type": "DRUG"
        },
        {
          "name": "Tolvaptan IR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 25,
      "start_date": "2010-10",
      "completion_date": "2011-06",
      "has_results": true,
      "last_update_posted_date": "2018-06-14",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Minneapolis, Minnesota • Rochester, Minnesota + 3 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01210560"
    },
    {
      "nct_id": "NCT02687451",
      "title": "Clinical Study to Evaluate the Effectiveness, Safety, and Tolerability of Oxymorphone Immediate Release (IR) Oral Liquid in Post Surgical Pediatric Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Post-Operative Pain",
        "Acute Pain"
      ],
      "interventions": [
        {
          "name": "Oxymorphone HCl",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Endo USA Inc., a Keenova Therapeutics Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": "2 Years",
        "sex": "ALL",
        "summary": "0 Years to 2 Years"
      },
      "enrollment_count": 28,
      "start_date": "2016-04",
      "completion_date": "2020-09-15",
      "has_results": true,
      "last_update_posted_date": "2021-10-26",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 3,
      "location_summary": "Durham, North Carolina • Dallas, Texas • Houston, Texas",
      "locations": [
        {
          "city": "Durham",
          "state": "North Carolina"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02687451"
    },
    {
      "nct_id": "NCT00323037",
      "title": "A Study to Compare the Effects of Coreg CR and Coreg IR on Heart Function in Subjects With Stable Chronic Heart Failure",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Congestive Heart Failure"
      ],
      "interventions": [
        {
          "name": "carvedilol controlled release",
          "type": "DRUG"
        },
        {
          "name": "carvedilol immediate release",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CTI-1, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 318,
      "start_date": "2006-03",
      "completion_date": "2008-06",
      "has_results": true,
      "last_update_posted_date": "2023-03-28",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 75,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 67 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00323037"
    },
    {
      "nct_id": "NCT02034331",
      "title": "IR and Microvascular Blood Flow in SCI",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Spinal Cord Injury",
        "Insulin Resistance"
      ],
      "interventions": [
        {
          "name": "Insulin iontophoresis",
          "type": "DRUG"
        },
        {
          "name": "Placebo Iontophoresis",
          "type": "DRUG"
        },
        {
          "name": "Acetylcholine Iontophoresis",
          "type": "DRUG"
        },
        {
          "name": "Heat application",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "James J. Peters Veterans Affairs Medical Center",
      "sponsor_class": "FED",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "20 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "20 Years to 69 Years"
      },
      "enrollment_count": 68,
      "start_date": "2012-12",
      "completion_date": "2016-12",
      "has_results": false,
      "last_update_posted_date": "2017-03-07",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 1,
      "location_summary": "The Bronx, New York",
      "locations": [
        {
          "city": "The Bronx",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02034331"
    },
    {
      "nct_id": "NCT06718686",
      "title": "Rifaximin SSD in Dementia Trial",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Dementia Alzheimer Type",
        "Dementia Associated With Cerebrovascular Disease"
      ],
      "interventions": [
        {
          "name": "Rifaximin SSD 40 mg IR tablet",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jasmohan Bajaj",
      "sponsor_class": "FED",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2024-12-30",
      "completion_date": "2027-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-03",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 1,
      "location_summary": "Richmond, Virginia",
      "locations": [
        {
          "city": "Richmond",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06718686"
    },
    {
      "nct_id": "NCT05297448",
      "title": "Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hepatic Encephalopathy"
      ],
      "interventions": [
        {
          "name": "Rifaximin SSD",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch Health Americas, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 466,
      "start_date": "2022-08-03",
      "completion_date": "2026-01",
      "has_results": false,
      "last_update_posted_date": "2025-09-10",
      "last_synced_at": "2026-09-05T03:39:53.020Z",
      "location_count": 90,
      "location_summary": "Homewood, Alabama • Chandler, Arizona • Sun City, Arizona + 70 more",
      "locations": [
        {
          "city": "Homewood",
          "state": "Alabama"
        },
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Bakersfield",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05297448"
    }
  ]
}